Category: Boston Scientific
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?: J&J demands $7.2 billion from Boston Scientific as trial begins; Will Orange County's medtech scene lose its juice without Allergan?; BD-CareFusion deal passes US anti-trust waiting period; Sources: Stryker weighs bid for Smith & Nephew
, Becton Dickinson & Co.
, Boston Scientific
, CareFusion Corp.
, Guidant Corp.
, Johnson & Johnson
, Smith & Nephew
, Stryker Corp.
, Valeant Pharmaceuticals
, Allergan Inc.
Researchers for the massive DAPT study find that drug-eluting stents may be safer than bare-metal stents, calling into question the value of Boston Scientific's next-gen Synergy stent.
Researchers for the massive Dual Anti-platelet Therapy Study found that patients receiving drug-eluting stents had a lower rate of stent thrombosis and other major cardiovascular events than those treated with bare-metal stents, undermining the common perception that bare-metal stents are safer.
The plaintiffs in 185 lawsuits filed against C.R. Bard over its Avaulta pelvic mesh as part of a multi-district litigation want their cases tried together.
Iowa Approach says it landed an investment from Boston Scientific for the ablation device it's developing to treat atrial fibrillation.
Here's a look at some of the top legal news stories for medical device companies this week: J&J demands $7.2 billion from Boston Scientific as trial begins; Bard still on the hook for its share of $5m pelvic mesh verdict; Boston Scientific to pay $18.5m in pelvic mesh case; Justice Dept. recoups $6B in False Claims Act cases
Back-to-back losses in pelvic mesh lawsuits could drive up the cost – and urgency – of settling thousands of other such cases for Boston Scientific, legal experts say.
The U.S. Justice Dept. says it recouped nearly $6 billion from civil cases alleging fraud and false claims against the federal government, including $2.3 billion from healthcare cases.
The U.S. Justice Dept. said it recouped a record $5.69 billion in settlements and judgments from False Claims Act cases during the fiscal year ended Sept. 30, including some $2.3 billion in recoveries from healthcare cases.